Last reviewed · How we verify
Pumecitinib Nasal Spray 0.6%
At a glance
| Generic name | Pumecitinib Nasal Spray 0.6% |
|---|---|
| Sponsor | Prime Gene Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis (PHASE3)
- A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pumecitinib Nasal Spray 0.6% CI brief — competitive landscape report
- Pumecitinib Nasal Spray 0.6% updates RSS · CI watch RSS
- Prime Gene Therapeutics Co., Ltd. portfolio CI